Oncología Traslacional
ONCTRAS
KU Leuven
Lovaina, BélgicaKU Leuven-ko ikertzaileekin lankidetzan egindako argitalpenak (53)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050
-
SENECA study: staging endometrial cancer based on molecular classification
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
-
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55
2023
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 188, pp. 131-139
-
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Gynecologic Oncology, Vol. 170, pp. 300-308
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Gynecologic Oncology, Vol. 164, Núm. 2, pp. 254-264
-
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Annals of Oncology, Vol. 33, Núm. 3, pp. 276-287
-
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial
Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
2021
-
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
International Journal of Gynecological Cancer, Vol. 31, Núm. 4, pp. 617-622
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
-
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors
International Journal of Gynecological Cancer, Vol. 31, Núm. 7, pp. 961-982
-
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors
Ultrasound in Obstetrics and Gynecology